Summary
- Profile Type
- Business Offer
- POD Reference
- BOGR20250403001
- Term of Validity
- 3 April 2025 - 3 April 2026
- Company's Country
- Greece
- Type of partnership
- Commercial agreement
- Supplier agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Greek research organisation has developed novel diagnostic kits that enhance the precision strategy for cancer treatment. Oncology clinics/hospitals, diagnostic laboratories, and/or academic institutions are sought to benefit from the organisation’s kits through commercial or supplier agreements.
- Full Description
-
A Greek research organization established in 1999 has developed an innovative platform dedicated to advancing oncology in IVD (in vitro diagnostic) healthcare technologies, through which it has developed two novel molecular kits that are currently in the market. These PCR-based tests have CE-IVD certification and are designed to detect cancer-related biomarkers in both peripheral blood and tumor samples from cancer patients. The kits have been protected through patents in the major market areas (including Europe, USA, Japan, Canada, China, Israel, Hong Kong, India) and National & European trademark. The organisation’s own R&D department developed the products using its privately owned manufacturing facilities, operating in accordance with all relevant quality standards and having been certified according to ISO 9001, 13485, DY8-1348-04 and GMP requirements.
One CE-IVD kit constitutes a ready-to-use kit for the detection of four gene mutations in exons 9 (Ε545Κ, Ε542Κ, Ε545Q) and 20 (Η1047R). The kit can be applied on DNA samples extracted from circulating tumor cells (CTCs), plasma and formalin-fixed paraffin-embedded (FFPE) tumor tissues samples of metastatic breast cancer patients. The kit includes sufficient reagents to analyze 24 clinical samples.
The other kit constitutes a ready-to-use kit for the determination of mRNA expression of a specific gene (PD-L1) using the Real Time-Polymerase Chain Reaction (PCR) method. The kit enables the measurement of PD-L1 overexpression in RNA samples extracted from CTCs in peripheral blood of metastatic NSCLC, HSNCC and melanoma cancer patients, providing information for monitoring and patients’ response to immunotherapy. The kit provides sufficient reagents to analyze 24 clinical samples.
The organisation seeks distributors and/or commercial partners that have established relationships with key stakeholders such as clinicians, diagnostic laboratories and health centres in the field of oncology that could benefit from the kits offered, through a commercial agreement. The aim is for the organization to become a regular supplier of such kits through a supplier agreement. - Advantages and Innovations
-
Detection of predictive biomarkers through the liquid biopsy approach requires sensitive, accurate and robust methods and it is the most competitive advantage of the products offered.
The organisation’s CE-IVD Kits provide:
• Easy set-up using ready-to-use reagents
• High sensitivity and specificity
• Compatibility with commonly used instrumentation
• Simple interpretation of results - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- Potential collaborators include oncology clinics/hospitals, diagnostic laboratories and universities focused on clinical research. Commercial and distribution partners are sought with expertise in the molecular diagnostics market, particularly in oncology-based IVD kits. These partners should have strong connections in the industry to help the company establish robust distribution channels and build a global customer base. Additionally, they should be experienced in the sales and support of PCR-based molecular diagnostic kits. The company will provide comprehensive technical support, training, and marketing materials to help achieve these objectives. Commercial and/or supplier agreements are envisaged.
- Type and Size of Partner
- SME 11-49
- SME 50 - 249
- University
- Type of partnership
- Commercial agreement
- Supplier agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001007 - Other diagnostic
- 05001005 - Molecular diagnosis
- 05001002 - In-vitro diagnostics
- Sector Groups Involved
- Health
- Targeted countries
- All countries